本文選題：喉鱗狀細胞癌 + CD44v6��； 參考：《山西醫(yī)科大學》2012年碩士論文

【摘要】：目的：研究腫瘤干細胞標志物CD44v6和CD133蛋白在喉癌組織與喉癌Hep-2細胞表達的相關性；探討其與喉癌患者臨床病理參數(shù)間的關系；分析腫瘤干細胞標志物CD44v6 和CD133蛋白作為喉癌干細胞標志物的合理性。 方法：選取病例資料齊全的喉鱗癌患者的組織蠟塊53例，收集20例喉癌旁正常組織及培養(yǎng)3組喉癌Hep-2細胞進行實驗研究。采用免疫組織化學及免疫細胞化學技術分別檢測53例喉鱗癌組織、20例喉癌旁正常組織及3組喉癌Hep-2細胞的CD44v6和CD133蛋白表達情況。采用SPSS17.0統(tǒng)計學軟件進行統(tǒng)計學分析，采用χ2檢驗或精確概率檢驗法（Fisher′exact test）比較CD44v6和CD133蛋白在喉癌不同臨床分型、不同T、N分期及不同分化程度之間的表達差異，檢驗水準α=0.05，以P0.05為差異有統(tǒng)計學意義。CD44v6和CD133蛋白之間的關聯(lián)分析采用Spearman秩相關分析，以P0.05為差異有統(tǒng)計學意義。 結果：CD44v6蛋白在喉癌組織與正常喉黏膜組織中陽性率分別為75.47%、30%，，有顯著性差異（P0.05)；CD133蛋白在喉癌組織與正常喉黏膜組織中陽性率分別為71.69%、25%，有顯著性差異（P0.05)。CD44v6蛋白表達陽性率與病理學分級、T分期相關（P0.05)，與臨床分型及有無頸淋巴結轉(zhuǎn)移組無相關性（P0.05）。CD133蛋白表達強度與病理分級、T分期及有無淋巴結轉(zhuǎn)移有關（P㩳0.05），與患者的臨床分型無關（P㧐0.05）。兩者在蛋白表達水平上有明顯相關性（P＜0.05），CD44v6和CD133陽性表達組術后生存期均短于陰性組（P＜0.05），但CD133陽性表達組較CD44v6陽性表達組明顯。喉癌Hep-2細胞的CD44v6蛋白陽性表達率分別為72%、75%、76%，平均為74.3%；CD133蛋白只在少數(shù)細胞中表達，絕大多數(shù)細胞不表達，陽性表達率分別為2.33%、2.61%、3.15%，平均為2.70%。 結論：腫瘤干細胞標志物CD44v6蛋白在喉癌組織與喉癌Hep-2細胞中有相似的陽性表達率，喉癌Hep-2細胞中CD133蛋白只在少數(shù)細胞中表達，大多數(shù)細胞不表達；CD44和CD133在喉鱗狀細胞癌的發(fā)生發(fā)展過程中發(fā)揮著一定的作用。CD44v6和CD133蛋白表達與喉癌的一些惡性特征有相關性，但是否可以作為喉癌干細胞的標志物尚需更多的實驗研究。
[Abstract]:Objective: to study the correlation between the expression of CD44v6 and CD133 protein in laryngeal carcinoma and Hep-2 cells, and to explore the relationship between CD44v6 and CD133 protein and the clinicopathological parameters of laryngeal carcinoma. To analyze the rationality of tumor stem cell markers CD44v6 and CD133 as stem cell markers of laryngeal carcinoma. Methods: 53 cases of laryngeal squamous cell carcinoma (LSCC) were collected from 53 cases of laryngeal squamous cell carcinoma (LSCC), 20 cases of normal tissue adjacent to laryngeal carcinoma and 3 groups of laryngeal carcinoma Hep-2 cells were collected for experimental study. The expression of CD44v6 and CD133 in 53 cases of laryngeal squamous cell carcinoma (LSCC) and 20 cases of normal tissues adjacent to laryngeal carcinoma and 3 groups of laryngeal carcinoma Hep-2 cells were detected by immunohistochemistry and immunocytochemistry respectively. SPSS 17.0 statistical software was used to analyze the expression of CD44v6 and CD133 proteins in different clinical types, stages and differentiation of laryngeal carcinoma by 蠂 2 test or exact probability test. The correlation between CD44v6 and CD133 protein was analyzed by Spearman rank correlation analysis. Results the positive rates of CD44v6 protein in laryngeal carcinoma and normal laryngeal mucosa were 75.47 and 30, respectively (P0.05). The positive rates of CD133 protein in laryngeal carcinoma tissues and normal laryngeal mucosa tissues were 71.690.There was significant difference (P0.05). CD44v6 protein expression was correlated with pathological grade and T stage (P0.05), but had no correlation with clinical type and cervical lymph node metastasis group (P0.05) .CD133. The expression intensity of protein was related to T stage of pathological grade and lymph node metastasis (P0. 05), but not to clinical type (P0. 05). The expression of CD44v6 and CD133 were significantly correlated (P < 0.05). The survival time of CD44v6 and CD133 positive expression group was shorter than that of negative group (P < 0.05), but the CD133 positive expression group was significantly higher than that of CD44v6 positive group (P < 0.05). The positive expression rates of CD44v6 protein in Hep-2 cells were 720.75 and 76.The average expression rate of CD133 was 74.3%. Most of the cells did not express CD44v6. The positive rates of CD44v6 protein were 2.33 ~ 2.61% and 3.15%, with an average of 2.70%. Conclusion: the expression rate of CD44v6 protein in laryngeal carcinoma is similar to that in laryngeal carcinoma Hep-2 cells. CD133 protein is expressed only in a few cells in laryngeal carcinoma Hep-2 cells, but not in most cells. CD44 and CD133 play a certain role in the development of laryngeal squamous cell carcinoma. The expression of CD44v6 and CD133 proteins is related to some malignant features of laryngeal carcinoma. However, more experimental research is needed on whether CD44 and CD133 can be used as markers of laryngeal carcinoma stem cells.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2012
【分類號】：R739.65

【參考文獻】

相關期刊論文 前10條

1 谷化平;尚培中;;CD44v6和PTEN表達與結直腸癌浸潤和轉(zhuǎn)移關系[J];青島大學醫(yī)學院學報;2008年01期

2 關小芳;文忠;申聰香;牟少鳳;張宏征;謝民強;郭夢和;;人鼻咽癌細胞株中類腫瘤干細胞的分離、培養(yǎng)及鑒定[J];解放軍醫(yī)學雜志;2008年12期

3 覃綱,黎萬榮,孫興旺,祝琳,陳正儂;CD44v6和MMP-9在喉鱗狀細胞癌組織中的表達及意義[J];臨床耳鼻咽喉科雜志;2005年15期

4 孫寶春;趙舒薇;周成勇;嚴清紅;王豪;;人喉組織中PD4和CD44以及PCNA蛋白的檢測及臨床意義[J];臨床耳鼻咽喉頭頸外科雜志;2010年18期

5 于欣;喬守怡;;腫瘤干細胞研究進展[J];中國生物工程雜志;2010年01期

6 谷化平;徐志勇;尚培中;;CD44v6和p63蛋白在喉鱗狀細胞癌中的表達及其意義[J];山西醫(yī)科大學學報;2006年01期

7 王明方,邢魯奇,張超;喉癌組織CD44蛋白表達及其臨床相關性研究[J];天津醫(yī)藥;2004年09期

8 王瑩穎;華清泉;張志堅;;CD44、CD133在頭頸部鱗狀細胞癌中的表達及臨床意義[J];現(xiàn)代預防醫(yī)學;2010年11期

9 魏茂富;楊延莉;劉鏡文;;CD44v6在乳腺癌及乳腺腺病中的表達及其臨床意義[J];中國現(xiàn)代醫(yī)生;2010年09期

10 宋新漢,彭解人,蔡翔,侯富林,林秋雄;CD44蛋白在人喉癌中的表達及其臨床意義[J];中國耳鼻咽喉顱底外科雜志;1999年02期

相關碩士學位論文 前1條

1 趙穎;人上皮性卵巢癌細胞中CD133和CD44的表達狀況及其功能研究[D];山東大學;2008年

本文編號：2073713